ArticleJCEM case reports2026
Prolactin receptor overexpression in pregnancy-associated Cushing syndrome and functional implications.
Article in JCEM case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cushing syndrome (CS) during pregnancy is rare but is associated with substantial maternal and fetal risks. Although aberrant activation of G protein-coupled receptors (GPCRs), particularly the luteinizing hormone/human chorionic gonadotropin receptor, has been implicated in pregnancy-related hypercortisolism, non-GPCR mechanisms remain incompletely defined. We report a case of adrenocorticotropic hormone-independent CS during pregnancy caused by a cortisol-producing adrenocortical adenoma. Integrative molecular analyses of the resected tumor, including ribonucleic acid sequencing and immunohistochemistry, demonstrated increased expression of the prolactin receptor (PRLR) compared with adjacent normal adrenal tissue. PRLR is a member of the type I cytokine receptor family and is expressed in normal adrenal glands; however, its potential role in adrenal tumors has not been well characterized. To examine its functional relevance, primary cell cultures derived from independent cortisol-producing adenomas from nonpregnant women were treated with recombinant prolactin (PRL). PRL induced a dose-dependent increase in both cortisol secretion into the culture medium and intracellular cortisol levels. Following unilateral adrenalectomy, hypercortisolism resolved, and maternal and neonatal outcomes were favorable. These data provide molecular and functional evidence supporting a contributory role of PRLR in pregnancy-associated hypercortisolism, potentially triggered by physiological PRL elevations during gestation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.